Table 3.

Serum TSH levels before and after hemithyroidectomy for DTC during a 3-year follow-up stratified by levothyroxine treatment in the open dynamic cohort design. Values indicate median and interquartile ranges. Wilcoxon signed-rank test was used to analyze statistical significance (pre- and post-hemithyroidectomy).

Patient groups	1-year post HT (n = 143)		2-year post HT (n = 134)*		3-year post HT (n = 130)†
	Complete	Missing	Complete	Missing	Complete	Missing
HT +/− LT4
TSH pre/post complete, n	116	27	106	28	96	34
Pre-HT TSH mIU/L	1.29 (0.81–1.91)	-	1.30 (0.82–1.92)	-	1.3 (0.78–1.93)	-
Post-HT TSH mIU/L	2.23 (1.71–3.16)	2.4 (1.70–3.16)	2.22 (1.58–3.06)	2.29 (1.69–2.81)	2.1 (1.45–2.87)	1.91 (1.49–2.71)
P-value	<0.0001	-	<0.0001	-	<0.0001	-
HT without LT4
TSH pre/post complete, n	93	22	73	20	63	23
Pre-HT TSH mIU/L	1.16 (0.74–1.64)	-	1.20 (0.74–1.64)	-	1.16 (0.79–1.70)	-
Post-HT TSH mIU/L	2.15 (1.71–3.0)	2.35 (1.69–3.16)	2.26 (1.70–3.06)	1.96 (1.22–2.39)	1.94 (1.38–2.65)	1.92 (1.50–2.50)
P-value	<0.0001	-	<0.0001	-	<0.0001	-
TSH 2–4 mIU/L, n (%)	68 (59)		46 (43)		36 (42)
HT with LT4
TSH pre/post complete, n	23	5	36	5	39	5
Pre-HT TSH mIU/L	2.45 (1.4–3.21)	-	1.98 (1.28–2.82)	-	1.98 (1.28–2.82)	-
TSH at LT4 initiation, mIU/L	6.25 (5.31–9.96)		5.80 (5.20–8.73)		5.88 (5.20–6.18)
Post-HT TSH mIU/L	3.01 (1.61–4.80)	2.40 (2.00–2.42)	2.13 (1.49–3.11)	2.61 (2.45–4.84)	2.48 (1.46–3.22)	1.6 (1.34–1.92)
P-value for pre vs post TSH	0.017	-	0.14	-	0.13	-

HT, hemithyroidectomy; TSH, thyroid-stimulating hormone; LT4; levothyroxine; DTC, differentiated thyroid cancer.

^*9 patients were excluded between the 1- and 2-year follow-up.

^† 4 patients were excluded between the 2- and 3-year follow-up.